Immunogenicity of Dendritic Cell-Based HPV16 E6/E7 Peptide Vaccines: CTL Activation and Protective Effects Cited by

Fol. Biol. 2004, 50, 184-193

https://doi.org/10.14712/fb2004050060184

Immunogenicity of Dendritic Cell-Based HPV16 E6/E7 Peptide Vaccines: CTL Activation and Protective Effects

Marie Indrová¹, M. Reiniš¹, J. Bubeník¹, T. Jandlová¹, J. Bieblová¹, V. Vonka², J. Velek³

¹Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
²Institute of Haematology and Blood Transfusion, Prague, Czech Republic
³Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic

Received October 2004
Accepted November 2004

Crossref Cited-by Linking

MIKY\u0160KOVÁ ROMANA, \u0160T\u011aPÁNEK IVAN, INDROVÁ MARIE, BIEBLOVÁ JANA, \u0160ÍMOVÁ JANA, TRUXOVÁ IVA, MOSEROVÁ IRENA, FU\u010cÍKOVÁ JITKA, BART\u016e\u0147KOVÁ JI\u0158INA, \u0160PÍ\u0160EK RADEK, REINI\u0160 MILAN: Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. International Journal of Oncology 2016, 48, 953. <https://doi.org/10.3892/ijo.2015.3314>